Spanish company KeyZell plans to reach 5 million euros to
Posted: Wed Dec 18, 2024 4:02 am
KeyZell, a Spanish biotechnology company currently in the development phase of treatments and digital tools against cancer, has just opened a private round of financing with which it hopes to reach 5 million euros to boost its projects and establish itself as one of the biotechnology start-ups with the greatest potential.
The company is launching this new round of private investment to conduct a clinical trial on humans with one of its innovative treatments, based on the research of Dr. Nabil Hajji on moj data cellular apoptosis induced by the blockage of cellular receptors, as well as to improve its Artificial Intelligence system for precision medicine, which aims to be the future of oncological medicine, thanks to an algorithm that proposes the most appropriate personalized treatment for each patient based on the unique characteristics of each person and type of cancer.
The startup has already generated great interest from both domestic private investors and North American investment funds, and has successfully closed a preliminary round of 450,000 euros, 50% above forecasts. Its investors include professional brokers and Spanish and Mexican entrepreneurs.
"We created KeyZell with the aim of developing new solutions and tools against cancer that can help both medical professionals and patients in their fight against this disease. This round of financing will allow us to achieve our ambitious goal," said Jose del Corral, CEO of the company.
"We are confident of raising the 5 million in this private round due to the great interest that the project has already generated among national and international investors. Our goal is to achieve double-digit growth in the next 4 years," he added.
You may also be interested in: The Orange Foundation and the Luis Vives Secondary School inaugurate a new GarageLab center
The company, which began as an altruistic project of its founders, is betting on blockchain technology in order to be able, on the one hand, to carry out clinical trials of its treatments and, on the other hand, to implement improvements to its tool based on artificial intelligence .
The startup has agreements with leading companies in the development of artificial intelligence systems and is negotiating agreements to carry out clinical trials on humans in Belgium, Mexico and Australia.
The company is launching this new round of private investment to conduct a clinical trial on humans with one of its innovative treatments, based on the research of Dr. Nabil Hajji on moj data cellular apoptosis induced by the blockage of cellular receptors, as well as to improve its Artificial Intelligence system for precision medicine, which aims to be the future of oncological medicine, thanks to an algorithm that proposes the most appropriate personalized treatment for each patient based on the unique characteristics of each person and type of cancer.
The startup has already generated great interest from both domestic private investors and North American investment funds, and has successfully closed a preliminary round of 450,000 euros, 50% above forecasts. Its investors include professional brokers and Spanish and Mexican entrepreneurs.
"We created KeyZell with the aim of developing new solutions and tools against cancer that can help both medical professionals and patients in their fight against this disease. This round of financing will allow us to achieve our ambitious goal," said Jose del Corral, CEO of the company.
"We are confident of raising the 5 million in this private round due to the great interest that the project has already generated among national and international investors. Our goal is to achieve double-digit growth in the next 4 years," he added.
You may also be interested in: The Orange Foundation and the Luis Vives Secondary School inaugurate a new GarageLab center
The company, which began as an altruistic project of its founders, is betting on blockchain technology in order to be able, on the one hand, to carry out clinical trials of its treatments and, on the other hand, to implement improvements to its tool based on artificial intelligence .
The startup has agreements with leading companies in the development of artificial intelligence systems and is negotiating agreements to carry out clinical trials on humans in Belgium, Mexico and Australia.